Skip to nav Skip to content

CDC/IDSA COVID-19 Clinician Call: Antibody Therapy under New EUA

Facebook Twitter LinkedIn Email

*This call was funded by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 6 NU50CK000477-04-01). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this call does not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.

These one-hour webinars, held Saturdays at 3 p.m. ET, focus on timely issues of relevance to clinicians and feature case presentations by experts in the field, synthesis of new data, and an opportunity to engage with colleagues. Register for next week here.


  • Dana S. Wollins, DrPH, MGC
    Vice President, Clinical Affairs & Practice Guidelines, IDSA

Featured Speakers and Presentations:

  • Janet Woodcock, M.D.
    On Detail As Therapeutic Lead
    Operation Warp Speed
    Director, Center for Drug Evaluation & Research, U.S. Food and Drug Administration

  • John T. Redd, M.D., MPH, FACP
    Chief Medical Officer
    Office of the Assistant Secretary for Preparedness and Response
    U.S. Department of Health and Human Services

Latest Media

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.